[ad_1]
Firm acknowledged for improvements in clinically validated cell remedy for corneal endothelial dystrophies
SEATTLE, BOSTON & TOKYO, October 27, 2022–(BUSINESS WIRE)–Aurion Biotech, whose mission is to revive imaginative and prescient to tens of millions of sufferers with its life-changing regenerative therapies, right this moment introduced it has gained the celebrated Prix Galien Award for Finest Startup in Biotech / Pharma. The Galien Basis, the premier world establishment devoted to honoring innovators in life sciences, fosters, acknowledges, and rewards excellence in scientific innovation to enhance the state of human well being.
This press launch options multimedia. View the complete launch right here: https://www.businesswire.com/news/home/20221027006159/en/
Prix Galien USA
“The Prix Galien is thought all through the world for its capacity to shine a brilliant mild on a very powerful, impactful improvements in drugs, biotechnology, healthcare and the life sciences,” stated Greg Kunst, Aurion Biotech chief government officer. “Aurion Biotech has a transformational alternative to positively influence the lives of tens of millions of individuals affected by corneal endothelial illnesses, with our exceptional, sight-restoring cell remedy. On behalf of our sufferers, workers, scientists and physicians, we thank the Galien Awards Committee for this unbelievable achievement for our firm.”
Aurion Biotech acquired the Finest Begin-up in Biotech / Pharma award, certainly one of six totally different award classes, and was chosen from greater than 146 merchandise from 129 nominee firms, spanning 14 therapeutic areas. The vetting course of was rigorous: nominees are invited to use for the Prix Galien award. Judges included leaders from enterprise capital, medical and tutorial establishments, and Fortune 1000 biomedical and pharmaceutical firms.
In accordance with the Galien Basis, the Prix Galien is considered the equal of the Nobel Prize in biopharmaceutical analysis. The Galien Basis oversees and directs actions within the US for the Prix Galien, a world awards program devoted to progress by way of revolutionary medicines growth, with chapters in 14 international locations and the continent of Africa. The Prix Galien was created in 1970 by Roland Mehl in honor of Galien, the daddy of medical science and trendy pharmacology. Within the final 50 years, solely a handful of ophthalmology merchandise have been awarded the Prix Galien.
Beforehand, Bernard Poussot, the Chair of Prix Galien Startup, Digital Well being and Incubators, Accelerators and Fairness Committee; Director of Roche Holding; and Former Chairman & CEO at Wyeth, has said, “The Prix Galien Awards have develop into probably the most coveted prizes for individuals who dedicate their lives to the event of significant medicine and improvements. Members of the Awards Committees applaud the unwavering dedication of every nominee of their quest to offer a more healthy future for the subsequent era.”
About Corneal Endothelial Ailments
Corneal edema secondary to endothelial dysfunction is a sight-threatening and debilitating situation affecting tens of millions of individuals all through the world. When corneal endothelial cells die or degrade, they don’t regenerate. In the end, corneal endothelial cell loss could cause corneal edema and lack of imaginative and prescient. Though corneal transplants are efficient, there are disadvantages with these procedures – PKP/DMEK/DSAEK1 – together with restricted donor organ provide. Transplants require a provide of donor corneas in a 1:1 ratio (one wholesome donor cornea to deal with every diseased one), but it’s estimated that there’s just one donor cornea accessible for each 70 diseased eyes.2 As well as, post-operative restoration for corneal transplant sufferers requires that they like flat on their backs for as much as three days, to ensure that the transplant to stick to the corneal stroma.
About Aurion Biotech
Based mostly in Seattle, Boston and Tokyo, Aurion Biotech is a clinical-stage biotech firm. Our mission is to revive imaginative and prescient to tens of millions of sufferers with our life-changing regenerative therapies. Our first candidate is for the therapy of corneal edema secondary to endothelial dysfunction, and is likely one of the first clinically validated cell therapies for corneal care. The Aurion Biotech group is getting ready for scientific trials within the U.S. The corporate is privately held, and backed by main buyers that embody Deerfield, Alcon, Petrichor, Flying L Companions, Falcon Imaginative and prescient / KKR, and Visionary Ventures. To study extra about Aurion Biotech, go to www.aurionbiotech.com.
1 Penetrating Keratoplasty, Descemets Membrane Endothelial Keratoplasty / Descemet Stripping Automated Endothelial Keratoplasty
2 JAMA: World Survey of Corneal Transplantation & Eye Banking: https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2474372
View supply model on businesswire.com: https://www.businesswire.com/news/home/20221027006159/en/
Contacts
Judith McGarry
415-971-2900
judith.mcgarry@aurionbiotech.com
Michele Grey
917-449-9250
michele@mgraycommunications.com
[ad_2]
Source link
